Last Price$63.3(0.2%)
Market Cap$14.7B
P/OCF LTM
13.2x
5Y avg
14.3x
Medical - Instruments & Supplies industry
median
11.7x
Stock quality & Intrinsic value
7/10
1.1% undervalued
Hologic, Inc. P/OCF LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Sep'05 | Sep'06 | Sep'07 | Sep'08 | Sep'09 | Sep'10 | Sep'11 | Sep'12 | Sep'13 | Sep'14 | Sep'15 | Sep'16 | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/OCF LTM | 25.9x | 58.4x | 31.2x | 15.8x | 8.6x | 8.8x | 9.0x | 13.0x | 11.3x | 14.9x | 16.5x | 13.5x | 149.9x | 16.8x | 21.0x | 23.8x | 8.4x | 6.5x | 17.7x | 16.1x |
Overvalued or undervalued?
Check the intrinsic value for HOLX
and see if it's the right time to invest.
Hologic, Inc. (HOLX) P/OCF LTM comparison analysis
General
LTM P/OCF LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Hologic, Inc.HOLX
11.7x
(0.0%)
81.1%
19.6%
Median Peer Set
26.0x
3.4%
15.9%
10.2%
Intuitive Surgical, Inc.ISRG
94.7x
17.2%
27.7%
27.8%
Repligen CorporationRGEN
54.3x
(21.1%)
(80.9%)
5.6%
Alcon Inc.ALC
53.5x
8.5%
182.9%
10.3%
Masimo CorporationMASI
52.7x
0.6%
(42.5%)
4.0%
The Cooper Companies, Inc.COO
26.2x
8.4%
32.2%
10.1%
West Pharmaceutical Services, Inc.WST
25.9x
(1.9%)
(15.5%)
17.0%
ResMed Inc.RMD
23.5x
10.9%
13.4%
21.8%
Becton, Dickinson and CompanyBDX
18.2x
4.2%
18.3%
8.4%
Baxter International Inc.BAX
17.6x
(69.5%)
(100.0%)
(6.9%)
AptarGroup, Inc.ATR
15.2x
2.7%
30.2%
10.5%
HOLX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Sep'05 | Sep'06 | Sep'07 | Sep'08 | Sep'09 | Sep'10 | Sep'11 | Sep'12 | Sep'13 | Sep'14 | Sep'15 | Sep'16 | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 287.7 25.8% | 462.7 60.8% | 738.4 59.6% | 1,674.5 126.8% | 1,637.1 (2.2%) | 1,679.6 2.6% | 1,789.3 6.5% | 2,002.7 11.9% | 2,492.3 24.4% | 2,530.7 1.5% | 2,705.0 6.9% | 2,832.7 4.7% | 3,058.8 8.0% | 3,217.9 5.2% | 3,367.3 4.6% | 3,776.4 12.1% | 5,632.3 49.1% | 4,862.8 (13.7%) | 4,030.4 (17.1%) | 4,030.3 (0.0%) |
| Cost of Goods Sold (COGS) | 174.7 | 269.1 | 392.8 | 782.0 | 779.6 | 942.9 | 866.2 | 1,008.2 | 1,330.9 | 1,285.2 | 1,272.3 | 1,269.4 | 1,437.8 | 1,521.2 | 2,059.2 | 1,548.9 | 1,836.5 | 1,865.4 | 1,958.9 | 1,802.5 |
% margin | 113.0 39.3% | 193.5 41.8% | 345.6 46.8% | 892.5 53.3% | 857.5 52.4% | 736.6 43.9% | 923.2 51.6% | 994.4 49.7% | 1,161.4 46.6% | 1,245.5 49.2% | 1,432.7 53.0% | 1,563.3 55.2% | 1,621.0 53.0% | 1,696.7 52.7% | 1,308.1 38.8% | 2,227.5 59.0% | 3,795.8 67.4% | 2,997.4 61.6% | 2,071.5 51.4% | 2,227.8 55.3% |
| Operating Expenses | 80.4 | 123.3 | 197.8 | 518.5 | 533.3 | 566.3 | 536.1 | 745.8 | 880.1 | 908.5 | 949.1 | 1,004.2 | 1,137.2 | 1,188.7 | 1,181.4 | 1,102.8 | 1,312.9 | 1,366.6 | 1,310.0 | 1,345.2 |
| Research & Development Expenses (R&D) | 18.6 | 28.3 | 44.5 | 81.4 | 94.3 | 104.3 | 116.7 | 131.0 | 197.6 | 203.2 | 214.9 | 232.1 | 232.8 | 218.7 | 232.2 | 222.5 | 276.3 | 283.4 | 294.3 | 272.8 |
| Selling, General & Administrative Expenses (SG&A) | 61.8 | 98.5 | 147.7 | 408.9 | 387.8 | 407.1 | 445.5 | 542.4 | 569.8 | 591.5 | 624.0 | 682.4 | 841.9 | 910.7 | 897.2 | 840.6 | 994.4 | 1,038.0 | 987.6 | 994.8 |
% margin | 32.6 11.3% | 50.3 10.9% | 147.8 20.0% | (197.5) (11.8%) | (2,016.7) (123.2%) | 69.9 4.2% | 374.4 20.9% | 113.7 5.7% | (906.3) (36.4%) | 279.7 11.1% | 455.1 16.8% | 548.6 19.4% | 1,370.2 44.8% | (237.9) (7.4%) | 134.4 4.0% | 1,105.0 29.3% | 2,480.3 44.0% | 1,640.2 33.7% | 668.4 16.6% | 882.6 21.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 4.5 | 1.2 | 1.3 | 1.9 | 2.3 | 1.3 | 1.3 | 1.3 | 0.7 | 3.8 | 6.3 | 4.6 | 4.3 | 1.4 | 12.9 | 120.5 | 108.7 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 84.9 | 73.2 | 126.2 | 114.8 | 140.3 | 281.1 | 220.6 | 205.5 | 155.3 | 153.2 | 148.7 | 140.8 | 116.5 | 93.6 | 95.1 | 111.1 | 122.1 |
| Pre-tax Income | 34.7 | 53.2 | 148.5 | (279.1) | (2,088.7) | (55.0) | 227.4 | (61.7) | (1,193.0) | 48.1 | 177.2 | 415.3 | 1,230.5 | (418.6) | (95.3) | 1,001.9 | 2,361.1 | 1,588.2 | 676.1 | 865.1 |
% effective tax rate | 6.4 18.6% | 25.8 48.5% | 53.9 36.3% | 106.5 (38.1%) | 87.6 (4.2%) | 7.8 (14.2%) | 70.2 30.9% | 12.0 (19.4%) | (20.1) 1.7% | 30.8 64.0% | 45.6 25.7% | 84.5 20.3% | 475.0 38.6% | (307.3) 73.4% | (55.1) 57.8% | (108.6) (10.8%) | 491.4 20.8% | 286.2 18.0% | 220.1 32.6% | 75.6 8.7% |
% margin | 28.3 9.8% | 27.4 5.9% | 94.6 12.8% | (385.6) (23.0%) | (2,176.2) (132.9%) | (62.8) (3.7%) | 157.2 8.8% | (73.6) (3.7%) | (1,172.8) (47.1%) | 17.3 0.7% | 131.6 4.9% | 330.8 11.7% | 755.5 24.7% | (111.3) (3.5%) | (40.2) (1.2%) | 1,115.2 29.5% | 1,871.5 33.2% | 1,302.0 26.8% | 456.0 11.3% | 789.5 19.6% |
| EPS | 0.33 | 0.30 | 0.88 | (1.57) | (8.48) | (0.24) | 0.60 | (0.28) | (4.36) | 0.06 | 0.47 | 1.18 | 2.70 | (0.40) | (0.15) | 4.24 | 7.28 | 5.18 | 1.85 | 3.35 |
| Diluted EPS | 0.32 | 0.28 | 0.86 | (1.57) | (8.48) | (0.24) | 0.59 | (0.28) | (4.36) | 0.06 | 0.45 | 1.16 | 2.64 | (0.40) | (0.15) | 4.21 | 7.21 | 5.13 | 1.83 | 3.32 |
% margin | 40.2 14.0% | 70.6 15.2% | 178.9 24.2% | (21.3) (1.3%) | (1,745.2) (106.6%) | 366.9 21.8% | 647.0 36.2% | 424.4 21.2% | (395.9) (15.9%) | 791.9 31.3% | 874.1 32.3% | 1,036.0 36.6% | 1,832.9 59.9% | 210.4 6.5% | 346.1 10.3% | 1,496.7 39.6% | 2,861.6 50.8% | 2,113.4 43.5% | 1,110.6 27.6% | 1,296.2 32.2% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Hologic, Inc.'s P/OCF LTM?
As of today, Microsoft Corp's last 12-month P/OCF LTM is 13.2x, based on the financial report for Dec 27, 2024 (Q4’2024). The average annual P/OCF LTM for Hologic, Inc. have been 12.3x over the past three years, and 15.0x over the past five years.
2) Is Hologic, Inc.'s P/OCF LTM Good?
As of today, Hologic, Inc.'s P/OCF LTM is 13.2x, which is higher than industry median of 11.7x. It indicates that Hologic, Inc.'s P/OCF LTM is Bad.